An observational study in Blood Stream Infections and Adult Cancer Patients, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Sohag University · Observational
Sepsis and bloodstream infection (BSI) are among the most serious complications in patients with cancer, in whom disease- and treatment-related immunosuppression markedly increases susceptibility to infection. Sepsis accounts for approximately 15% of ICU admissions in this population, and short-term mortality is consistently higher than in patients without cancer In haematological malignancy, sepsis affects roughly 12-27% of patients within a year of diagnosis, and although in-hospital mortality has fallen over two decades, it remained higher than in non-cancer patients (23.1% vs 14.4% in 2021) .
BSI in these patients is often complicated by polymicrobial infection and multidrug-resistant organisms, which are associated with worse outcomes, and early identification of high-risk patients is therefore essential to optimize empirical therapy and guide escalation of care. Because blood culture results take days, the outcome of an episode depends largely on the quality of the empirical antibiotic choice made before the pathogen and its susceptibility are known.
That choice is becoming progressively harder because of antimicrobial resistance (AMR), one of the most serious global health threats of the 21st century. The spread of multidrug-resistant organisms, such as ESBL-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), and methicillin-resistant Staphylococcus aureus (MRSA), has narrowed the reliable options for empirical treatment.
Clinicians usually rely on local antibiograms, guidelines, and personal experience, which do not capture patient-specific risk factors or rapidly changing resistance patterns at the ward level. Consequently, regimens tend to be either too broad, driving further resistance, or too narrow, risking treatment failure, and inappropriate empirical therapy is consistently associated with higher mortality in bacteraemia.
Phenotypic susceptibility testing tells us whether an isolate is resistant, but not why. Molecular characterization of resistant isolates identifies the underlying genes and lineages and can explain the predicted phenotype. For instance, whole-genome sequencing of CRE bloodstream isolates from patients with hematological malignancies showed a predominance of ST11 and blaKPC-2 among carbapenem-resistant Klebsiella pneumoniae. Linking clinical prediction with genomic data could therefore make a predictive model more interpretable and more useful for surveillance.
Sohag University is the lead sponsor of 1,218 studies on the registry; 627 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult Cancer Patients with Blood Stream Infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
o Adult patients (≥18 years) with a confirmed diagnosis of solid or hematological malignancy.
Exclusion Criteria:
o Patients younger than 18 years.
Adult cancer patients with blood stream infections
Diagnostic Test: Identification of bacterial isolates causing blood stream infection and determination of their antibiotic sensitivity · Diagnostic Test: Molecular characterization of bacterial isolates
Blood Culture: Blood samples will be collected under complete aseptic conditions. Blood culture bottles will immediately be transported to the Medical Microbiology Laboratory and tested using the BD BACTEC blood culture system. Identification and antibiotic sensitivity of bacterial isolates: Positive blood culture bottles will be identified and tested for antimicrobial sensitivity using the VITEK® 2 Compact system (bioMérieux, France).
A subset of bacterial isolates collected during the prospective phase will undergo molecular characterization to enable integration of molecular resistance determinants with clinical and laboratory variables.
Identification of bacterial isolates causing blood stream infection and determination of their antibiotic sensitivity
Blood Culture: BD BACTEC blood culture system. Identification and antibiotic sensitivity of bacterial isolates: VITEK® 2 Compact system (bioMérieux, France).
Time frame: From enrollment up to 6 months.
Molecular characterization of bacterial isolates
A subset of bacterial isolates collected during the prospective phase will undergo molecular characterization to enable integration of molecular resistance determinants with clinical and laboratory variables.
Time frame: From the end of enrollment up to 6 months.
Plan to share: No
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.